<DOC>
	<DOCNO>NCT00038194</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose docetaxel combination Gleevec ( imatinib mesylate ) give men advance androgen-independent metastatic prostate cancer involve bone . Docetaxel commercial chemotherapy interfere cancer cell ability divide grow .</brief_summary>
	<brief_title>Phase I Trial Fixed Dose STI571 ( Imatinib Mesylate ) With Escalating Doses Docetaxel Patients With Metastatic Androgen-Independent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : 1 . To define maximum tolerate dose weekly docetaxel combination fixed-dose oral STI571 adult men metastatic androgen-independent prostate cancer ( AIPC ) . 2 . To determine qualitative quantitative toxicity combination oral STI571 docetaxel . 3 . Evaluate PSA modulation STI571 alone thirty day patient AIPC . 4 . Obtain preliminary estimate response rate AIPC combination STI571 docetaxel . 5 . Obtain tissue correlative science study ( optional study ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion : Patients histologic proof adenocarcinoma prostate must progress conventional hormonal therapy . Patients must bone metastasis demonstrate bone scan . Lytic bone lesion consider biopsy clinical suspicion histologic conversion small cell carcinoma . Patients must evidence progression disease . PSA progression define 2 consecutive increment PSA ( absolute change least 1ng/mL ) 4 week . An increase 25 % product bidimensional disease qualifies progression . An increase number metastatic lesion bone scan qualifies progression . All patient must minimum PSA 1ng/ml . Patients antiandrogens discontinue flutamide nilutamide least 4 week bicalutamide 8 week . If progression document prior time interval , patient eligible . Patients must performance status &lt; 2 ( ECOG ) . Patients must expect survival cancer comorbidity least three month . Patients may receive concurrent chemotherapy , immunotherapy ketoconazole . Patients receive prior chemotherapy radiation within last 30 day Strontium Samarium within last 90 day . Patients must castrate serum testosterone level ( &lt; 30ng/dl ) . For patient medically castrate , luteinizing hormone release hormone analog must continue maintain testicular suppression . Patients must adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 . Patients adequate hepatic function define bilirubin &lt; 1.5 mg/dl AST/ALT &lt; 2X upper limit normal . Patients adequate renal function define serum creatinine clearance &gt; 40 cc/min ( measure calculate Cockcroft Gault formula ) serum creatinine &lt; 1.5 X upper limit normal . Fully recover previous surgery ( least 4 week since major surgery . Patients must sign informed consent indicate aware investigational nature study , keep policy institution . The approved consent attach protocol . Exclusion : Patients severe intercurrent infection . Patients whose tumor contain small cell sarcomatoid element . Patients NYHA Class III/IV CHF , unstable angina MI last 6 month evidence active myocardial ischemia ECG . CNS metastases uncontrolled . Prior hypersensitivity doselimiting toxicity docetaxel . Oxygendependent lung disease Contraindications corticosteroid . Uncontrolled severe hypertension uncontrolled diabetes mellitus . Second malignancy ( except nonmelanoma skin cancer ) unless diseasefree 3 year . Overt psychosis mental disability otherwise incompetent give inform consent . Patients history noncompliance medical regimen consider potentially unreliable .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>